Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)

Next Previous
X
Search
Trial Profile

A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary) ; YH 003 (Primary)
  • Indications Adenocarcinoma; Ductal carcinoma; Malignant melanoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Eucure Biopharma

    • Most Recent Events

    • 04 Jun 2024 Results (n=92) assessing safety and efficacy of YH003 in combination with toripalimab in patients with unresectable/metastatic pancreatic ductal adenocarcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Sep 2023 Planned End Date changed from 1 Mar 2023 to 1 Jan 2024.
    • 12 Sep 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top